A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OFDEUCRAVACITINIB IN ADOLESCENT PARTICIPANTS (12 YEARS TO LESS THAN 18YEARS) WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Intervention/treatment:
DEUCRAVACITINIB (BMS-986165)
Medical condition:
PLAQUE PSORIASIS
Protocol code:
IM011-1128
Control number:
298334
Status:
Recruiting
Approved:
June 23, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06979453
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
12 Years to 17 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role
CONTACT
Phone:
855-907-3286
Name
First line of the email MUST contain NCT # and Site #.
Role
CONTACT
Sponsor
BRISTOL-MYERS SQUIBB CANADA

Locations

Alberta

Alberta Dermasurgery Centre
Edmonton, Alberta, T6G 1C3
RECRUITING
Name
Jaggi Rao, Site 0241
Role
CONTACT
Phone:
587-487-0187

Manitoba

Local Institution - 0164
Winnipeg, Manitoba, R3C 0N2
NOT_YET_RECRUITING
Name
Site 0164
Role
CONTACT

Newfoundland and Labrador

Skincare Studio
St. John's, Newfoundland and Labrador, A1E 1V4
RECRUITING
Name
Tracey Brown-Maher, Site 0242
Role
CONTACT
Phone:
709-728-1563

Ontario

AvantDerm
Toronto, Ontario, M5A 3R6
RECRUITING
Name
Davindra Singh, Site 0156
Role
CONTACT
Phone:
(416) 869-3376
DermEffects
London, Ontario, N6H 5L5
RECRUITING
Name
Wei Jing Loo, Site 0143
Role
CONTACT
Phone:
2269197887
Local Institution - 0240
Toronto, Ontario, M5G 1X8
NOT_YET_RECRUITING
Name
Site 0240
Role
CONTACT
The Centre for Dermatology
Richmond Hill, Ontario, L4B 1A5
RECRUITING
Name
Mani Raman, Site 0144
Role
CONTACT
Phone:
905-889-2005

Quebec

Local Institution - 0142
Montreal, Quebec, H3T 1C5
NOT_YET_RECRUITING
Name
Site 0142
Role
CONTACT
Did you find what you were looking for?

Contacts and resources